App

Anti-cancer drugs more accessible for clinical use in China
Updated: May 10, 2021 21:14 Xinhua

BEIJING — Hospitals in China saw a 15 percent increase in 2020 in the variety of anti-cancer drugs with negotiated price cuts compared with 2019.

The data was based on results from a monitoring network that covers more than 1,400 hospitals across China, Guo Yanhong, an official with the National Health Commission, told a press conference on May 10. 

In 2018, 17 anti-cancer drugs were included in China's medical insurance reimbursement list, with their prices cut by 56.7 percent on average after a round of price negotiations between the National Healthcare Security Administration and pharmaceutical companies.

The hospitals under the monitoring network purchased 450.8 percent more of the 17 anti-cancer drugs on average in 2020 than in 2018, Guo said, adding that the accessibility of anti-cancer drugs for clinical use has increased.

Copyright© www.gov.cn | About us | Contact us

Website Identification Code bm01000001 Registration Number: 05070218

All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to www.gov.cn.

Without written authorization from www.gov.cn, such content shall not be republished or used in any form.

Mobile

Desktop

Copyright© www.gov.cn | Contact us

Website Identification Code bm01000001

Registration Number: 05070218